Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
December 24, 2018
OncoImmunology

UCSD study suggests that combination of APOBEC-related mutagenesis and tumor mutation burden may be used as a biomarker of response to immunotherapy.

CTD²
December 21, 2018
Nature Communications

Researchers at DFCI analyzed genome-scale loss-of-function datasets and identified adenosine deaminase acting on RNA as a gene dependency in subsets of lung cancer.

CTD²
December 17, 2018
Cold Spring Harbor Molecular Case Studies

Scientists report that two myeloid leukemia cases with FMS-like tyrosine kinase (FLT3) fusions demonstrate mixed features of myelodysplastic and myeloproliferative syndromes; showed sensitivity to FLT3 inhibitors in ex vivo drug screening assays.

CTD²
December 13, 2018
Cell

CTD2 scientists at Stanford University demonstrated that air-liquid interface patient-derived tumor organoid models retain the original tumor immune cells, enabling testing for personalized immunotherapy in cancer.

CTD²
November 29, 2018
Cell Chemical Biology

Scientists at the Emory University CTD2 Center developed the High-Throughput immunomodulator Phenotypic (HTiP) screening platform to explore PPI inhibitors, as immunomodulators. This screening identified the Inhibitor of Apoptosis Protein (IAP) as anti-tumor immunity enhancers.

CTD²
November 29, 2018
Journal of Molecular Cell Biology

CTD2 researchers at Emory University identify novel role for large tumor suppressor 2, LATS2, as a regulator of the ASK1-mediated stress response pathway which may lead to new strategies to control cellular response to stress in normal cells and diseases.

CTD²
November 28, 2018
Cell Systems

UCSF scientists developed a bioinformatic approach, MAGNETIC, which integrates multi-omic data from cancer patients with pharmacogenomic data from cell lines into a small set of pathway-enriched gene modules. These modules connect tumor and cell line biomarkers and may inform therapeutic targets.

CTD²
November 26, 2018
Nature Medicine

UCSF (1) CTD2 researchers identified a synthetic lethal interaction between EGFR tyrosine kinase inhibitors and Aurora kinase inhibitors in acquired resistant cells. This study suggests combinatorial treatment to prevent treatment resistance with the monotherapies.

CTD²
November 13, 2018
Blood

CTD2 scientists at Oregon Health and Science University performed genetic and small-molecule screens and identified CSF1R as a novel therapeutic target of acute myeloid leukemia.

Pages

CSVXML